Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 123,538,400
  • Shares Outstanding, K 599,701
  • Annual Sales, $ 23,747 M
  • Annual Income, $ 8,394 M
  • 60-Month Beta 1.19
  • Price/Sales 5.15
  • Price/Cash Flow 11.29
  • Price/Book 11.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 3.47
  • Number of Estimates 10
  • High Estimate 3.61
  • Low Estimate 3.35
  • Prior Year 3.69
  • Growth Rate Est. (year over year) -5.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
173.12 +18.73%
on 07/26/19
211.90 -3.00%
on 08/13/19
+27.16 (+15.23%)
since 07/19/19
3-Month
166.68 +23.32%
on 05/31/19
211.90 -3.00%
on 08/13/19
+37.16 (+22.07%)
since 05/20/19
52-Week
166.30 +23.60%
on 05/15/19
211.90 -3.00%
on 08/13/19
+7.99 (+4.04%)
since 08/20/18

Most Recent Stories

More News
Here's Why Allergan is Outperforming Its Industry Of Late

Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.

AGN : 160.85 (+1.00%)
ABBV : 67.57 (+1.52%)
RHHBY : 34.6701 (-0.77%)
AMGN : 205.54 (-0.22%)
California Life Sciences Association Adds Substantial Depth to Board with Several New Appointments

California Life Sciences Association (CLSA), the trade association representing California's life sciences sector, today announced the appointment of several new members to CLSA's Board of Directors. Joining...

MDT : 108.35 (+4.00%)
AMGN : 205.54 (-0.22%)
Axsome Therapeutics Appoints David Marek as Chief Commercial Officer

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment...

AMGN : 205.54 (-0.22%)
AXSM : 24.89 (+0.12%)
AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA

AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives FDA approval for treating rheumatoid arthritis under the trade name of Rinvoq. Shares up.

NVS : 89.37 (-0.12%)
ABBV : 67.57 (+1.52%)
AMGN : 205.54 (-0.22%)
BIIB : 232.69 (-1.29%)
Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?

Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

GHDX : 74.48 (+0.35%)
AMGN : 205.54 (-0.22%)
BIIB : 232.69 (-1.29%)
ALXN : 112.92 (+0.21%)
Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More

Key highlights of the past week include collaborations, and other regulatory and pipeline news.

AMRN : 15.25 (-2.62%)
ALNY : 83.04 (+1.02%)
GILD : 63.96 (-0.23%)
REGN : 299.91 (+0.51%)
AMGN : 205.54 (-0.22%)
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

CELG : 95.46 (+0.25%)
VRTX : 186.45 (-0.34%)
GILD : 63.96 (-0.23%)
REGN : 299.91 (+0.51%)
AMGN : 205.54 (-0.22%)
ALXN : 112.92 (+0.21%)
Here's Why Amgen Stock is Outperforming Its Industry Of Late

Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.

AGN : 160.85 (+1.00%)
NVS : 89.37 (-0.12%)
RHHBY : 34.6701 (-0.77%)
AMGN : 205.54 (-0.22%)
Mergers & Acquisitions Take Center Stage in Biotech Industry

Mergers & Acquisitions Take Center Stage in Biotech Industry

CELG : 95.46 (+0.25%)
VRTX : 186.45 (-0.34%)
GILD : 63.96 (-0.23%)
REGN : 299.91 (+0.51%)
AMGN : 205.54 (-0.22%)
BIIB : 232.69 (-1.29%)
ALXN : 112.92 (+0.21%)
Should Value Investors Choose Amgen (AMGN) Stock Now?

Let's see if Amgen (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.

AMGN : 205.54 (-0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 209.93
1st Resistance Point 207.96
Last Price 205.54
1st Support Level 202.57
2nd Support Level 199.15

See More

52-Week High 211.90
Last Price 205.54
Fibonacci 61.8% 194.48
Fibonacci 50% 189.10
Fibonacci 38.2% 183.72
52-Week Low 166.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar